Celgene price target raised to $145 from $131 at Cantor Cantor increased its price target on Celgene, citing the strength of the company's underlying business, as well as its new product flow. The firm expects the company's EPS to trend upward through this year, and it keeps a Buy rating on the shares
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.